Cite

HARVARD Citation

    Zhu, S. et al. (2022). DNA‐repair status should be assessed in treatment‐emergent neuroendocrine prostate cancer before platinum‐based therapy. Prostate. 82 (4), pp. 464-474. [Online]. 
  
Back to record